Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd plus durvalumab versus Dato-DXd alone in PD-L1-negative metastatic triple-negative breast cancer
ISRCTN67463316Phase 2Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Jul 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of datopotamab deruxtecan and durvalumab in triple-negative breast cancer (TNBC), sponsored by Queen Mary University of London. Started Jul 2025; status: recruiting.
02
Drugs
datopotamab deruxtecandurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ISRCTN67463316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN67463316.